Biotech Blog Archives: June 2002
next page ·
previous page
19 June 2002
5 Big Drug Companies Face R&D Drought
5 Big Drug Companies Face R&D Drought
Five of the world’s biggest drug companies do not have any potential billion-dollar drugs in late-stage development, highlighting the industry’s current poor R&D productivity, according to a report released on Wednesday.
continue reading... » 0 Comments
19 June 2002
Informatics Moves to the Head of the Class
Informatics Moves to the Head of the Class
The race is on to increase the quantity and quality of bio-IT training programs as government and academia bet the need will be great. Will the job market back that up?
continue reading... » 0 Comments
18 June 2002
Nanopharmaceuticals Open Up Brand New Field Of Study
Nanopharmaceuticals Open Up Brand New Field Of Study
Drug-binding molecules tiny enough to travel through the body’s smallest capillaries may provide a way to spare the heart and other organs from the toxic effects of drug overdose.
continue reading... » 0 Comments
17 June 2002
Networked Pharma
Networked Pharma
The pharmaceutical industry is experiencing a deepening productivity crisis. The industry’s preferred escape mechanism from this predicament has been to increase investment in current business activities - primarily R&D and sales - to sustain productivity levels or, ideally, to exploit economies of scale. This has been implemented through organic growth of critical resources and/or [...]
continue reading... » 0 Comments
17 June 2002
Pharma Financial Squeeze Bodes Ill for Genomics
Pharma Financial Squeeze Bodes Ill for Genomics
‘Caution: Tougher Times Ahead’ may be an apt sign for biotech in general and genomics in particular, according to a panel of leading venture capitalists.
continue reading... » 0 Comments
14 June 2002
DeCode’s Genetic Breakthrough Barely Registers
DeCode’s Genetic Breakthrough Barely Registers
DeCode Genetics published an important genetic map–assembled by methods very different from those used to create the sequence of the human genome–that will make it much easier for scientists to hunt down new genes linked to disease. But DeCode’s stock continues to languish.
